Markets

Achillion Pharmaceuticals (ACHN) in Focus: Stock Falls 6.4% - Tale of the Tape

Achillion Pharmaceuticals, Inc. ( ACHN ) saw a big move last session, as the company's shares fell by over 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for ACHN, as the stock is now up nearly 162% since Jun 2.

The biopharmaceutical company has seen a flat track record when it comes to current year estimate revisions over the past few weeks, and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

ACHN currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the same sector include ANI Pharmaceuticals, Inc. ( ANIP ), Gilead Sciences Inc. ( GILD ) and Illumina Inc. ( ILMN ). All these stocks hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ANIP ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More